Supernus Pharmaceuticals (SUPN) PT Set at $55.00 by Cowen

Supernus Pharmaceuticals (NASDAQ:SUPN) has been assigned a $55.00 price target by research analysts at Cowen in a report released on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cowen’s price objective suggests a potential upside of 15.98% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Supernus Pharmaceuticals in a research note on Friday, November 23rd. Piper Jaffray Companies reissued a “hold” rating and set a $44.00 price objective on shares of Supernus Pharmaceuticals in a research note on Thursday, August 9th. Jefferies Financial Group lifted their price target on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Finally, ValuEngine lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 6th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $55.90.

NASDAQ:SUPN opened at $47.42 on Friday. The firm has a market cap of $2.48 billion, a P/E ratio of 37.63, a price-to-earnings-growth ratio of 1.49 and a beta of 0.92. Supernus Pharmaceuticals has a 52-week low of $34.90 and a 52-week high of $61.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million during the quarter, compared to analyst estimates of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the company earned $0.29 earnings per share. Equities research analysts anticipate that Supernus Pharmaceuticals will post 1.87 EPS for the current year.

A number of hedge funds have recently modified their holdings of SUPN. SevenBridge Financial Group LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth about $113,000. Quantbot Technologies LP bought a new stake in Supernus Pharmaceuticals during the third quarter worth about $113,000. Cubist Systematic Strategies LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth about $203,000. NumerixS Investment Technologies Inc purchased a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $204,000. Finally, Gryphon Financial Partners LLC increased its holdings in shares of Supernus Pharmaceuticals by 302.5% in the third quarter. Gryphon Financial Partners LLC now owns 4,037 shares of the specialty pharmaceutical company’s stock worth $204,000 after buying an additional 3,034 shares during the period. 97.83% of the stock is owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: What impact do institutional investors have on markets?

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit